^
Association details:
| Biomarker: | PIK3CA I391M |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Excerpt:
At concentrations ≥0.01 μg/mL, sensitivity to T-DM1 was observed across all cell lines with various activating PIK3CA mutations (Fig. 3).
DOI:
10.1158/1078-0432.CCR-15-2499
